EDGAR·FLOW

ROCKWELL MEDICAL, INC. — Form 8-K

Filed November 12, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 87/100
What the filing says
Rockwell Medical (market cap ~$28.7M) reported Q3 2026 net sales of $19.1M (+20% YoY) and gross profit of $3.1M (+37% YoY), but posted net loss of $2.3M. The company announced an Equity and Asset Purchase Agreement to acquire Vantive's hemodialysis business (concentrates, machines, water treatment systems, consumables) and a 1M-sq-ft manufacturing campus in Medolla, Italy. The combined entity is projected to generate $400–450M annual revenue. Transaction-related expenses of $847K appear in Q3 2026 results; specific acquisition price and financing terms are not disclosed in this filing.
Why this rating

Vantive acquisition is transformational for a $28.7M company—projected post-deal revenue of $400–450M is 7–8× current annualized run rate. Adds significant product portfolio, manufacturing footprint, and global reach. Financing and close conditions remain uncertain.

Tradability signal
NO TRADE

No trade: positive news with only +0.6% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=451). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$7.15
+10 min · unknown
$7.10 ▼ 0.70%
+30 min · unknown
$6.99 ▼ 2.24%
+1 hr · unknown
$6.99 ▼ 2.24%
+4 hrs · unknown
$7.53 ▲ 5.31%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ RMTI · stock on Yahoo Finance ↗

See more from November 12, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.